Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (22,360)
  • Open Access

    ERRATUM

    Long Noncoding RNA PlncRNA-1 Promotes Colorectal Cancer Cell Progression by Regulating the PI3K/Akt Signaling Pathway

    Wei Song*, Jia-Zhuan Mei, Mingzhi Zhang

    Oncology Research, Vol.28, No.9, pp. 971-972, 2020, DOI:10.3727/096504022X16414984936791

    Abstract Accumulating evidence has indicated that long noncoding RNA (lncRNA) PlncRNA-1 plays an important regulatory role in cancers. However, the expression and biological functions of PlncRNA-1 in colorectal cancer (CRC) are still unclear. In the present study, we determined the expression of PlncRNA-1 in CRC and explored the function of PlncRNA-1 on CRC cell progression. The results showed that PlncRNA-1 was significantly increased in CRC tissues and cell lines; high PlncRNA-1 expression was associated with depth of invasion, lymph node metastasis, and TNM stage of CRC patients. Kaplan–Meier curve analysis showed that patients with high PlncRNA-1 expression had a poor overall… More >

  • Open Access

    ERRATUM

    Kallistatin Suppresses Cell Proliferation and Invasion and Promotes Apoptosis in Cervical Cancer Through Blocking NF-κB Signaling

    Tao Wang, Fan Shi, JiQuan Wang, Zi Liu, Jin Su

    Oncology Research, Vol.28, No.9, pp. 969-970, 2020, DOI:10.3727/096504022X16414984936773

    Abstract Kallistatin has been recognized as an endogenous angiogenesis inhibitor and exerts pleiotropic effects in inhibiting tumor growth, migration, apoptosis, and inflammation. The purpose of the present study was to investigate the potential role and mechanisms of kallistatin in cervical cancer. We demonstrated that kallistatin effectively inhibited cell proliferation and enhanced apoptosis in a dose-dependent manner. Additionally, kallistatin suppressed migration and invasion activities and markedly reduced the expression of matrix-degrading metalloproteinases, progelatinase (MMP-2), MMP-9, and urokinase-type PA (uPA). Kallistatin reversed the epithelial–mesenchymal transition (EMT) and caused the upregulation of epithelial markers such as E-cadherin and inhibited mesenchymal markers such as N-cadherin… More >

  • Open Access

    ERRATUM

    miR-132 Targets FOXA1 and Exerts Tumor-Suppressing Functions in Thyroid Cancer

    Xin Chen*, Mingzhe Li, Hongwei Zhou*, Li Zhang*

    Oncology Research, Vol.28, No.9, pp. 965-967, 2020, DOI:10.3727/096504022X16414984936764

    Abstract MicroRNA-132 (miR-132) has been demonstrated to be a tumor suppressor in several types of tumors. However, the expression and the role of miR-132 in human thyroid cancer are still poorly understood. The aim of the present study was to examine the potential roles and molecular mechanism of miR-132 in thyroid cancer. We found that miR-132 expression levels were significantly downregulated in thyroid cancer tissues and cell lines. Function assays showed that overexpression of miR-132 in TPC1 cells inhibited cell proliferation, migration, and invasion. Forkhead box protein A1 (FOXA1) was identified as a direct target of miR-132 in thyroid cancer cells.… More >

  • Open Access

    ERRATUM

    Downregulation of MicroRNA-147 Inhibits Cell Proliferation and Increases the Chemosensitivity of Gastric Cancer Cells to 5-Fluorouracil by Directly Targeting PTEN

    Jianjun Shen*1, Weina Niu†1, Hongbo Zhang*, Ma Jun*, Hongyan Zhang*

    Oncology Research, Vol.28, No.9, pp. 961-963, 2020, DOI:10.3727/096504022X16414984936746

    Abstract Gastric cancer is the fourth most common malignancy and the third leading cause of cancer-related deaths worldwide. This study aimed to investigate the expression patterns, biological roles, and underlying mechanisms of microRNA-147 (miR-147) in gastric cancer. The present study demonstrated that miR-147 was significantly upregulated in gastric cancer tissues and cell lines. Downregulation of miR-147 decreased cell proliferation and enhanced the chemosensitivity of gastric cancer cells to 5-fluorouracil (5-FU) through the cell apoptosis pathway. In addition, phosphatase and tensin homolog (PTEN) was mechanically identified as the direct target of miR-147 in gastric cancer. PTEN knockdown reversed the effects of miR-147… More >

  • Open Access

    ARTICLE

    Long Noncoding RNA LAMTOR5-AS1 Interference Affects MicroRNA-506-3p/ E2F6-Mediated Behavior of Non-Small Cell Lung Cancer Cells

    Guojie Chen*1, Kai Wang*1, Guoshu Li†1, Leidong Wang, Yangyang Xiao§, Bo Chen

    Oncology Research, Vol.28, No.9, pp. 945-959, 2020, DOI:10.3727/096504021X16328213967104

    Abstract Long noncoding RNA LAMTOR5 antisense RNA 1 (LAMTOR5-AS1) has been certified as a risk predictor and diagnostic biomarker of prostate cancer. However, the expression and exact roles of LAMTOR5-AS1 in nonsmall cell lung cancer (NSCLC) remain unclear. Thus, we measured LAMTOR5-AS1 expression in NSCLC and gauged its clinical value. The detailed roles and downstream working mechanism of LAMTOR5-AS1 in NSCLC were comprehensively unraveled. qRT-PCR was applied to measure gene expression. Functionally, utilizing small interfering RNA, LAMTOR5-AS1 was ablated, and the functional alterations were addressed by means of different experiments. The targeting activities between LAMTOR5-AS1 and microRNA-506-3p (miR-506-3p) and between miR-506-3p… More >

  • Open Access

    ARTICLE

    Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer

    Heming Lu*†1, Yuying Wu‡1, Xu Liu, Huixian Huang, Hailan Jiang, Chaohua Zhu, Yuping Man§, Zhaohong Chen, Xianfeng Long, Qiang Pang, Luxing Peng, Xianglong Li, Junzhao Gu, Shan Deng, Ligang Xing*

    Oncology Research, Vol.28, No.9, pp. 929-944, 2020, DOI:10.3727/096504021X16318716607908

    Abstract This phase II randomized clinical trial aimed to assess the efficacy and toxicity of Endostar, an antiangiogenesis inhibitor, combined with concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC). Patients with LACC were randomly assigned to either CCRT plus Endostar (CCRT+E arm) or CCRT alone (CCRT arm). All patients received pelvic intensity-modulated radiation therapy (IMRT) and brachytherapy. Weekly cisplatin was administered concurrently with IMRT. Patients in the CCRT+E arm also received concurrent Endostar every 3 weeks for two cycles. The primary endpoint was progression-free survival (PFS) and acute toxicities. The exploratory endpoint was the impact of vascular endothelial growth factor… More >

  • Open Access

    ARTICLE

    Long Noncoding RNA LINC01703 Exacerbates the Malignant Properties of Non-Small Cell Lung Cancer by Upregulating MACC1 in a MicroRNA-605-3p-Mediated Manner

    Ziyi Wang*, Xinyu Zhang*, Xuedong Zhang, Xuedong Jiang, Wenya Li*

    Oncology Research, Vol.28, No.9, pp. 913-927, 2020, DOI:10.3727/096504021X16310057751016

    Abstract Long intergenic nonprotein-coding RNA 1703 (LINC01703) has diagnostic significance in lung adenocarcinoma. However, its specific roles in non-small cell lung cancer (NSCLC) and downstream mechanisms have not been investigated. In the current study, we characterized the role of LINC01703 in NSCLC malignancy and elucidated its detailed mechanism of action. LINC01703 expression was measured by qRT-PCR. The regulatory effects of LINC01703 on the malignancy of NSCLC cells were assessed by multiple functional experiments. The targeted interaction was confirmed by RNA immunoprecipitation and luciferase reporter assays. Herein, overexpression of LINC01703 in NSCLC was indicated in the TCGA database and further proven in… More >

  • Open Access

    ARTICLE

    A Combined Chemical, Computational, and In Vitro Approach Identifies SBL-105 as Novel DHODH Inhibitor in Acute Myeloid Leukemia Cells

    Hossam Kamli*, Gaffar S. Zaman*, Ahmad Shaikh*, Abdullah A. Mobarki, Prasanna Rajagopalan*‡

    Oncology Research, Vol.28, No.9, pp. 899-911, 2020, DOI:10.3727/096504021X16281573507558

    Abstract Inhibition of the dihydroorotate dehydrogenase (DHODH) has been successful at the preclinical level in controlling myeloid leukemia. However, poor clinical trials warrant the search for new potent DHODH inhibitors. Herein we present a novel DHODH inhibitor SBL-105 effective against myeloid leukemia. Chemical characteristics were identified by 1 H NMR, 13C NMR, and mass spectroscopy. Virtual docking and molecular dynamic simulation analysis were performed using the automated protocol with AutoDock-VINA, GROMACS program. Human-recombinant (rh) DHODH was used for enzyme inhibition study. THP-1, TF-1, HL-60, and SKM-1 cell lines were used. MTT assay was used to assess cell viability. Flow cytometry was… More >

  • Open Access

    ARTICLE

    miR-142-5p Inhibits Cell Invasion and Migration by Targeting DNMT1 in Breast Cancer

    Hui Li*1, Han-Han Li†1, Qian Chen‡1, Yu-Yang Wang, Chang-Chang Fan, Yuan-Yuan Duan, You Huang, Hui-Min Zhang, Jia-Peng Li, Xiao-Yu Zhang, Yuan Xiang, Chao-Jiang Gu, Li Wang§, Xing-Hua Liao, Tong-Cun Zhang‡¶

    Oncology Research, Vol.28, No.9, pp. 885-897, 2020, DOI:10.3727/096504021X16274672547967

    Abstract Abnormal cell proliferation caused by abnormal transcription regulation mechanism seems to be one of the reasons for the progression of breast cancer and also the pathological basis. MicroRNA-142-5p (miR-142-5p) is a low-expressed miRNA in breast cancer. The role of MKL-1’s regulation of DNMT1 in breast cancer cell proliferation and migration is still unclear. MKL-1 (myocardin related transcription factor A) can bind to the conserved cis-regulatory element CC (A/T) 6GG (called CarG box) in the promoter to regulate the transcription of miR-142-5p. The expressions of miR-142-5p and MKL-1 are positively correlated. In addition, it has been proved that DNMT1 is the… More >

  • Open Access

    ARTICLE

    uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma Cells

    Elena Andreucci*1, Anna Laurenzana*, Silvia Peppicelli*, Alessio Biagioni*, Francesca Margheri*, Jessica Ruzzolini*, Francesca Bianchini*, Gabriella Fibbi*, Mario Del Rosso*†, Chiara Nediani*, Simona Serratì, Livia Fucci§, Michele Guida, Lido Calorini*†1

    Oncology Research, Vol.28, No.9, pp. 873-884, 2020, DOI:10.3727/096504021X16273798026651

    Abstract Malignant melanoma is a highly aggressive skin cancer characterized by an elevated grade of tumor cell plasticity. Such plasticity allows adaptation of melanoma cells to different hostile conditions and guarantees tumor survival and disease progression, including aggressive features such as drug resistance. Indeed, almost 50% of melanoma rapidly develop resistance to the BRAFV600E inhibitor vemurafenib, with fast tumor dissemination, a devastating consequence for patients’ outcomes. Vasculogenic mimicry (VM), the ability of cancer cells to organize themselves in perfused vascular-like channels, might sustain tumor spread by providing vemurafenibresistant cancer cells with supplementary ways to enter into circulation and disseminate. Thus, this… More >

Displaying 7511-7520 on page 752 of 22360. Per Page